Cargando…
Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease constitutes the most prevalent hereditary kidney disease, associated with high rates of morbidity leading eventually to end-stage renal disease. Tolvaptan is a selective vasopressin antagonist and has emerged as a promising therapeutic option for patients...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254589/ https://www.ncbi.nlm.nih.gov/pubmed/34234441 http://dx.doi.org/10.2147/TCRM.S286952 |